Document is current
Any future updates will be listed below
-
Authors
Liotta, Lance A. https://orcid.org/0000-0001-5155-7907
Conrads, Thomas P.
Howard, Marissa A.
Araujo, Robyn P. https://orcid.org/0000-0002-3360-2214
Petricoin, Emanuel F.
- License Information
-
More Information
Article History
Accepted: 14 November 2025
First Online: 24 December 2025
Competing interests
: L.A.L., E.F.P. and M.A.H. are inventors of LCM-related patents (8,628,931 B2, 9,383,299, 9,029,076 B2, 10,126,304 B2, 10,823,738, 10,690,672, 11,493,518 B2, 11, 747,242, 12,188,852, 202180088971.4, 202180089205.X, 21892671.5, 18/461,041, 18/241,790, 61/169,518) assigned to George Mason University or NIH that are licensed to outside biomedical companies by the University or NIH under NIH-royalty guidelines. M.A.H is a consultant from Targeted Bioscience LLC relating to interstitial fluid extracellular vesicle collection. T.P.C. is a Thermo Fisher Scientific Inc. SAB member and receives research funding from AbbVie, Inc. E.F.P. receive royalties from and is a consultant of TheraLink Technologies Inc. E.F.P. is a shareholder and consultant of Avant Diagnostics, TheraLink Technologies Inc. and Perthera. E.F.P. received funding support from Mirati Therapeutics, Genentech Inc. and Abbvie Inc. R.P.A. declares no competing interests.
